Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., D’Hollander, K., . . . Di Leo, A. (2018). Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol.
Citación estilo ChicagoMalorni, L., et al. "Palbociclib As Single Agent or in Combination With the Endocrine Therapy Received Before Disease Progression for Estrogen Receptor-positive, HER2-negative Metastatic Breast Cancer: TREnd Trial." Ann Oncol 2018.
Cita MLAMalorni, L., et al. "Palbociclib As Single Agent or in Combination With the Endocrine Therapy Received Before Disease Progression for Estrogen Receptor-positive, HER2-negative Metastatic Breast Cancer: TREnd Trial." Ann Oncol 2018.